Porownywarka
Setmelanotide vs Liraglutide side-by-side
Zestaw do czterech peptydów według statusu dowodów, mechanizmów, dawkowania z badań, skutków ubocznych i referencji.
Porownywarka
Zestaw do czterech peptydów według statusu dowodów, mechanizmów, dawkowania z badań, skutków ubocznych i referencji.
Wybrane (2/4)
Udostępnij porównanie peptydów
| Wlasciwosc | Setmelanotide | Liraglutide |
|---|---|---|
| Kategoria | Redukcja masy | Redukcja masy |
| Znany tez jako | Imcivree, RM-493 | Victoza, Saxenda |
| Zatwierdzony przez FDA | Tak | Tak |
| Status kliniczny | FDA approved for specified rare obesity indications including BBS, POMC/PCSK1/LEPR deficiency, and acquired hypothalamic obesity.
| FDA approved for diabetes as Victoza and weight loss as Saxenda; source also reports Teva generic Saxenda launched Aug 2025.
|
| Czego oczekiwac | Genetic obesity disorders and rare metabolic conditions | Weight management, diabetes control, appetite suppression |
| Jak dziala | Setmelanotide is reported as a melanocortin-4 receptor agonist. The supplied mechanism evidence places MC4R downstream of leptin and POMC signaling in hypothalamic appetite regulation. For rare conditions such as POMC, PCSK1, or LEPR deficiency, the source states that upstream signaling can be impaired while MC4R remains a target; direct MC4R agonism is therefore presented as the rationale for its narrow genetic-obesity use. | Liraglutide is reported to act as a GLP-1 receptor agonist. The source describes glucose-dependent pancreatic insulin signaling, reduced glucagon activity, delayed gastric emptying, and central appetite-related GLP-1 receptor activity in the hypothalamus as mechanisms relevant to glucose control and satiety. |
| Typowe dawkowanie | 2-3 mg daily · Once daily · Subcutaneous injection | 1.8-3 mg daily · Once daily · Subcutaneous injection daily |
| Dawkowanie z badań | 2-3 mg daily in adults · Long-term / chronic use · Subcutaneous injection daily | 0.6mg daily (starting) · Once daily · Long-term / chronic use · Subcutaneous injection daily |
| Typowy czas trwania | Long-term / chronic use | Long-term / chronic use |
| Podanie | Subcutaneous injection | Subcutaneous injection daily |
| Timing | Beginning of the day Without regard to meals | Morning or evening, consistent daily With or without food |
| Poziom dowodów | Zatwierdzone przez FDA | Zatwierdzone przez FDA |
| Mozliwe skutki uboczne |
+4 więcej
|
+7 więcej
|
| Podsumowanie researchu | The supplied source summarizes clinical evidence as narrow but strong for rare disease populations. It reports pivotal open-label, single-arm phase 3 studies in POMC and LEPR deficiency, with at least 10% weight loss at about one year in 80% of POMC participants and 45% of LEPR participants, plus reduced hunger scores. The source also cites a randomized placebo-controlled phase 3 study for Bardet-Biedl syndrome and a 2024 VENTURE open-label study including children as young as two. Because the conditions are rare, the evidence base is described as small and indication-specific rather than broadly applicable to common obesity. | The source characterizes liraglutide evidence as human clinical evidence rather than preliminary research. It reports that the LEADER trial enrolled 9,340 high-risk participants with type 2 diabetes and found cardiovascular death, heart attack, or stroke occurred in 13.0% with liraglutide versus 14.9% with placebo, published in the New England Journal of Medicine in 2016. For weight outcomes, the source cites the SCALE program, where adults without diabetes lost about 8% of body weight at 56 weeks on the 3.0 mg Saxenda dose. It also notes that nausea, vomiting, and diarrhea are common, particularly during dose escalation, and that labeling includes a boxed warning for thyroid C-cell tumors based on rodent findings without a confirmed human link. |
| Referencje | ||
| Pełny profil | Zobacz szczegóły | Zobacz szczegóły |
Zapisz to porównanie
Trzymaj ten zestaw researchowy pod reka na darmowym koncie PeptiGuide.
Zapisz porównanie - darmowe kontoTrackuj swoja ścieżkę peptydówa
Zamien research w prywatny log protokołu, gdy będziesz gotowy.
Trackuj ścieżkę peptydówaWyłącznie edukacyjnie. Te informacje są agregowane z publicznych badań i raportów społeczności. To nie jest poradą medyczną, a informacje o dawkowaniu są opisowe, nie rekomendacyjne. Zawsze konsultuj się z wykwalifikowanym specjalistą ochrony zdrowia.